In the US, Alefacept (alefacept systemic) is a member of the drug class selective immunosuppressants and is used to treat Psoriasis.
US matches:
- Alefacept
- Alefacept; water, sterile Intramuscular, Intravenous
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L04AA15
CAS registry number (Chemical Abstracts Service)
0222535-22-0
Chemical Formula
C3264-H5002-N840-O988-S20
Molecular Weight
72740
Therapeutic Categories
Selective immunosuppressant
Antipsoriatic
Chemical Name
1-92-antigen LFA-3 (human) fusion protein with human immunoglobulin G1 (hinge-CH2-CH3 gamma1-chain), dimer (WHO)
Foreign Names
- Alefaceptum (Latin)
- Alefacept (German)
- Aléfacept (French)
- Alefacept (Spanish)
Generic Names
- Alefacept (OS: USAN, BAN)
- BG 9273 (IS: Biogen)
- BG 9712 (IS: Biogen)
- Human LFA 3IgG fusion protein (IS)
- Leukocyte function-associated antigen-3 (IS)
- LFA 3 (IS)
- LFA 3CD2 (IS)
- LFA 3TIP (IS: Biogen)
- LFA-(92)IgG (IS)
- Recombinant LFA-3/IgG1 fusion protein (IS)
Brand Names
- Amevive
Astellas, Canada; Biogen, United States
International Drug Name Search
Glossary
BAN | British Approved Name |
IS | Inofficial Synonym |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
WHO | World Health Organization |
Click for further information on drug naming conventions and
International Nonproprietary Names.